US EditionImpact of MFP Effectuation on Pharmacies and Beneficiaries
Summary by Avalere Health
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Impact of MFP Effectuation on Pharmacies and Beneficiaries
Background The Inflation Reduction Act mandates that the Centers for Medicare & Medicaid Services (CMS) negotiate a Maximum Fair Price (MFP) for a set number of drugs each year. To date, 10 Part D drugs have been negotiated for the Initial Price Applicability Year (IPAY) 2026, with an additional 15 Part D drugs selected for IPAY 2027. After CMS negotiates MFPs, manufacturers must provide access to the MFP to Medicare beneficiaries and to pharmac…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
